Event
Vitestro secures $22 million (€20 million) for autonomous blood draw device
Key points
- Vitestro announced a $22 million (€20 million) funding round for its autonomous blood draw device.
- The raise added capital ahead of CE-marking and broader commercialization.
- The round sits as the main disclosed funding event before the 2026 Series B.
Company context
Develops autonomous robotic blood collection systems for clinical settings. Its Aletta platform is an autonomous robotic phlebotomy device that uses multimodal imaging, robotics, and AI to identify veins, insert the needle, collect diagnostic blood tubes, and complete the venous blood draw workflow. The company is focused on hospital and outpatient diagnostic workflows, with CE-marked deployment in Europe and U.S. regulatory work underway.
Context
- Company
- Vitestro
- Segment
- Healthcare
- Event type
- Funding
- Geography
- Utrecht · Netherlands